glycine has been researched along with Anemia, Refractory, with Excess of Blasts in 1 studies
Anemia, Refractory, with Excess of Blasts: Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silverman, LR | 1 |
| Greenberg, P | 1 |
| Raza, A | 1 |
| Olnes, MJ | 1 |
| Holland, JF | 1 |
| Reddy, P | 1 |
| Maniar, M | 1 |
| Wilhelm, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine[NCT01928537] | Phase 3 | 67 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk[NCT00906334] | Phase 2 | 14 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS[NCT00854646] | Phase 1 | 22 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glycine and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |